Gadolinium-based contrast agents (GBCAs) are contraindicated in patients with severe renal failure (eGFR <30) primarily because of the risk of:

• A Nephrogenic systemic fibrosis (NSF) ✓
• B Gadolinium-induced nephropathy similar to iodinated CIN
• C Anaphylactoid reaction to the gadolinium chelate
• D CNS deposition causing gadolinium encephalopathy

Explanation

Nephrogenic systemic fibrosis (NSF) is a devastating fibrosing disorder of skin, subcutaneous tissue, and internal organs associated with gadolinium-based contrast agents in patients with severe renal failure (eGFR <30 mL/min/1.73m²) or on dialysis. Impaired renal clearance leads to prolonged gadolinium tissue exposure and chelate decomplexation, releasing free gadolinium ions. Linear GBCAs (less stable) carry higher risk than macrocyclic agents. Gadolinium does not cause CIN at diagnostic doses. Gadolinium CNS deposition is a recognized phenomenon but without proven clinical toxicity in renal function.

Reference: Grainger & Allison's Diagnostic Radiology, 7th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.